Dimitrios Vlastos

Mr. Dimitrios Vlastos


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 January 2018 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
VLVaia Lambadiari
Vaia Lambadiari
George PavlidisGeorge Pavlidis
George Pavlidis
FKFoteini Kousathana
Foteini Kousathana
MVMaria Varoudi
Maria Varoudi
DVDimitrios Vlastos
Dimitrios Vlastos
Ignatios IkonomidisIgnatios Ikonomidis
Ignatios Ikonomidis
Background: Incretin-based therapies are used in the treatment of type 2 diabetes mellitus (T2DM) and obesity. We investigated the changes in arterial stiffness and left ventricular (LV) myocardial deformation after 6-month treatment with the GLP-1 analogue liraglutide in subjects with newly diagnosed T2DM. Methods: We randomized 60 patients with newly diagnosed and treatment-naive T2DM to receive either liraglutide (n = 30) or metformin (n = 30) for 6 months. We measured at baseline and after 6-month treatment: (a) carotid-femoral pulse wave velocity (PWV) (b) LV longitudinal strain (GLS), and strain rate (GLSR), peak twisting (pTw), peak twisting velocity (pTwVel) and peak untwisting velocity (pUtwVel) using speckle tracking echocardiography. LV untwisting was calculated as the percentage difference between peak twisting and untwisting at MVO (%dpTw–UtwMVO), at peak (%dpTw–UtwPEF) and end of early LV diastolic filling (%dpTw–UtwEDF) (c) Flow mediated dilatation (FMD) of the brachial artery and percentage difference of FMD (FMD%) (d) malondialdehyde (MDA), protein carbonyls (PCs) and NT-proBNP. Results: After 6-months treatment, subjects that received liraglutide presented with a reduced PWV (11.8 ± 2.5 vs. 10.3 ± 3.3 m/s), MDA (0.92 [0.45–2.45] vs. 0.68 [0.43–2.08] nM/L) and NT-proBNP (p < 0.05) in parallel with an increase in GLS (− 15.4 ± 3 vs. − 16.6 ± 2.7), GLSR (0.77 ± 0.2 vs. 0.89 ± 0.2), pUtwVel (− 97 ± 49 vs. − 112 ± 52°, p < 0.05), %dpTw–UtwMVO (31 ± 10 vs. 40 ± 14), %dpTw–UtwPEF (43 ± 19 vs. 53 ± 22) and FMD% (8.9 ± 3 vs. 13.2 ± 6, p < 0.01). There were no statistically significant differences of the measured markers in subjects that received metformin except for an improvement in FMD. In all subjects, PCs levels at baseline were negatively related to the difference of GLS (r = − 0.53) post-treatment and the difference of MDA was associated with the difference of PWV (r = 0.52) (p < 0.05 for all associations) after 6-month treatment. Conclusions: Six-month treatment with liraglutide improves arterial stiffness, LV myocardial strain, LV twisting and untwisting and NT-proBNP by reducing oxidative stress in subjects with newly diagnosed T2DM. ClinicalTrials.gov Identifier NCT03010683

2 January 2020 in Journal of Cardiovascular Translational Research
Verified
Journal Article
Closed access
PDF file
STStavros Tzortzis
Stavros Tzortzis
Ignatios IkonomidisIgnatios Ikonomidis
Ignatios Ikonomidis
HTHELEN TRIANTAFYLLIDI
HELEN TRIANTAFYLLIDI
PTParaskevi Trivilou
Paraskevi Trivilou
George PavlidisGeorge Pavlidis
George Pavlidis
JLJohn Lekakis
John Lekakis

21 January 2026 in European Journal of Vascular and Endovascular Surgery
Verified
Journal Article
Open access
NKNikolaos Konstantinou
Nikolaos Konstantinou
DVDimitrios Vlastos
Dimitrios Vlastos
ASAthanasios Saratzis
Athanasios Saratzis
Nicola TroisiNicola Troisi
Nicola Troisi
MDMario D’ORia
Mario D’ORia
KRKevin Roy
Kevin Roy
To report peri-operative and midterm outcomes following open surgical, endovascular, and hybrid revascularisation for acute lower limb ischaemia (ALLI) using contemporary techniques and to provide adjusted comparative analyses accounting for key baseline differences. This was a multicentre, retrospective study including patients treated for ALLI (January 2016 - November 2024) across 20 international vascular centres. Patients underwent open surgery (56%), endovascular treatment (20%), or hybrid procedures (24%). Primary outcome was major amputation and or death at the latest follow up. Secondary outcomes included peri-operative mortality, amputation, acute kidney injury, and re-intervention. Multivariable Cox regression analyses adjusted for age, sex, Rutherford stage, and chronic kidney disease were performed. A Fine-Gray competing risk model accounted for death as a competing event for major amputation. A total of 1 259 patients (51% men; mean age 72 ± 14 years; no popliteal aneurysms) from 19 European centres and one centre in New Zealand were included. At 30 days, peri-operative mortality was 11% (open 12%, endovascular 3%, hybrid 7%; p = .04), and major amputation occurred in 9% (open 10%, endovascular 8%, hybrid 7%; p = .41). Median follow up was 36 months (range 8 - 49 months). At 3 years, estimated mortality was 22.9% (standard error [SE] 1.5%) after open, 11.5% (SE 1.9%) after endovascular, and 19.6% (SE 2.2%) after hybrid procedures. Adjusted analyses demonstrated that endovascular treatment was associated with a lower risk of the composite outcome of major amputation and or death compared with open surgery (hazard ratio 0.69, 95% confidence interval [CI] 0.53 - 0.89; p = .005). For major amputation, the Fine-Gray competing risk analysis showed a reduced subdistribution hazard with endovascular treatment (subdistribution hazard ratio 0.71, 95% CI 0.33 - 0.99; p = .006). Endovascular ALLI intervention was associated with lower long term amputation risk compared with open surgery, with comparable survival. These findings support endovascular treatment as a safe alternative in patients with ALLI.

14 September 2021 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
DVDimitrios Vlastos
Dimitrios Vlastos
ICIshaansinh Chauhan
Ishaansinh Chauhan
KMKwabena Mensah
Kwabena Mensah
MCMaria Cannoletta
Maria Cannoletta
AAAthanasios Asonitis
Athanasios Asonitis
GAGeorge Asimakopoulos
George Asimakopoulos
Background: The coronavirus-disease 2019 (COVID-19) pandemic imposed an unprecedented burden on the provision of cardiac surgical services. The reallocation of workforce and resources necessitated the postponement of elective operations in this cohort of high-risk patients. We investigated the impact of this outbreak on the aortic valve surgery activity at a single two-site centre in the United Kingdom.Methods: Data were extracted from the local surgical database, including the demographics, clinical characteristics, and outcomes of patients operated on from March 2020 to May 2020 with only one of the two sites resuming operative activity and compared with the respective 2019 period. A similar comparison was conducted with the period between June 2020 and August 2020, when operative activity was restored at both institutional sites. The experience of centres world-wide was invoked to assess the efficiency of our services.Results: There was an initial 38.2% reduction in the total number of operations with a 70% reduction in elective cases, compared with a 159% increase in urgent and emergency operations. The attendant surgical risk was significantly higher [median Euroscore II was 2.7 [1.9–5.2] in 2020 versus 2.1 [0.9–3.7] in 2019 (p = 0.005)] but neither 30-day survival nor freedom from major post-operative complications (re-sternotomy for bleeding/tamponade, transient ischemic attack/stroke, renal replacement therapy) was compromised (p > 0.05 for all comparisons). Recommencement of activity at both institutional sites conferred a surgical volume within 17% of the pre-COVID-19 era.Conclusions: Our institution managed to offer a considerable volume of aortic valve surgical activity over the first COVID-19 outbreak to a cohort of higher-risk patients, without compromising post-operative outcomes. A backlog of elective cases is expected to develop, the accommodation of which after surgical activity normalisation will be crucial to monitor.

29 June 2022 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
APAina Pons
Aina Pons
PSPaulo De Sousa
Paulo De Sousa
CPChiara Proli
Chiara Proli
SBSarah A Booth
Sarah A Booth
APAbigail Palmares
Abigail Palmares
ELEric Lim
Eric Lim
We sought to evaluate the impact of different national clinical guidelines (with consistent and conflicting recommendations) on clinician’s practice in the UK. In this cohort study, we analysed data from National Lung Cancer Audit comprising all patients diagnosed with lung cancer between 2008 and 2013 within England and Wales for consistent (British Thoracic Society and National Institute of Clinical Excellence) recommendations for lower/more permissive lung function but opposing stage (N2) selection parameters for surgery. From 2008 to 2013, data from 167 192 patients with primary lung cancers were included. The proportion of patients undergoing surgery for lung cancer increased from 9.5% to 20.5% in 2013 (P < 0.001) as the number of general thoracic surgeons in the UK increased from 40 to 81 in the corresponding timeframe. Mean forced expiratory volume in 1 s of surgical patients increased from 76% (22) to 81% (22) in 2013 (P < 0.001). Of the patients undergoing surgery, the proportion of patients with N2 disease across the 6-year interval was broadly consistent between 8% and 11% without any evidence of trend (P = 0.125). Within 3 years of new clinical guideline recommendations, we did not observe any overall change suggesting greater selection for surgery on lower levels of lung function. When presented with conflicting recommendation, no observable change in selection was noted on surgery for N2 disease. The observed increase in surgical resection rates is more likely due to greater access to surgery (by increasing number of surgeons) rather than any impact of guideline recommendations.

31 August 2019 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
DADimitrios C. Angouras
Dimitrios C. Angouras
MMMaria Mademli
Maria Mademli
DVDimitrios Vlastos
Dimitrios Vlastos
DDDimitrios Dougenis
Dimitrios Dougenis